Objective: To assess the feasibility of a fit-for-purpose exergaming intervention in youth (6–18 years old) with spinal muscular atrophy (SMA) and neurotypical controls. Background: The nature of how best to promote the recommended frequency of physical activity in youth with SMA is evolving. The use of active videogames for rehabilitation (exergaming) has a positive impact on motivation towards training, is flexible in scheduling, and has proven impact on enhancing strength, coordination, and mobility in other conditions. We have developed a home-based exergame (Tales from the Magic Keep™) specifically for youth with neuromuscular disorders in which functional upper limb and trunk movements are tracked by the Microsoft® Kinect Azure sensor. Design/Methods: We conducted a 4-week open label feasibility study across two Canadian sites. The exergaming intervention was used at home by participants at a target dose of 20 minutes four times a week. Feasibility of the game was determined by assessing adherence, acceptability, and need for game adaptation. Adherence was quantified by the motion detector from the Azure Microsoft Kinect Platform and verified against a weekly participant reported log. A Likert scale was used to evaluate the perceived value, experience, satisfaction, and need for adaptation regarding the exergame. Usability was assessed using the System Usability Scale. Results: Ten youth with SMA and five neurotypical controls were enrolled. Results of the feasibility study will be presented. Conclusions: Exergaming was found to be acceptable and enjoyable to youth with a wide range of abilities. Therapy gamification has the potential to increase physical activity in youth with SMA and other neuromuscular disorders. Disclosure: Dr. Oskoui has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for the Association des Neurologues du Quebec. The institution of Dr. Oskoui has received research support from Biogen. The institution of Dr. Oskoui has received research support from Roche Genetech. The institution of Dr. Oskoui has received research support from Muscular Dystrophy Canada. The institution of Dr. Oskoui has received research support from Canadian Institutes of Health Research. Dr. Oskoui has received personal compensation in the range of $50,000-$99,999 for serving as a Methodologist with American Academy of Neurology. Dr. Oskoui has a non-compensated relationship as a Member of the Medical and Scientific Advisory Committee with Muscular Dystrophy Canada that is relevant to AAN interests or activities. The institution of Dr. Selby has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Dr. Selby has received research support from Biogen . The institution of Dr. Selby has received research support from Italfarmico. The institution of Dr. Selby has received research support from Reverogen. Mr. Herzig has received personal compensation for serving as an employee of F. Hoffmann - La Roche AG. Mr. Herzig has stock in F. Hoffmann - La Roche AG. Mr. Herzig has received personal compensation in the range of $5,000-$9,999 for serving as a Lecturer with FHNW. Mrs. Cardiff has nothing to disclose. Miss Cushen has nothing to disclose. Mr. Défossés has nothing to disclose. Dr. Gonorazky has received personal compensation for serving as an employee of Novartis. Dr. Gonorazky has received personal compensation for serving as an employee of Biogen. Dr. Gonorazky has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Gottowik has received personal compensation for serving as an employee of F. Hoffmann–La Roche Ltd. Renee Haldenby has received personal compensation for serving as an employee of Hoffmann-LaRoche Ltd. Mr. Jurisic has received personal compensation for serving as an employee of Roche. Miss Karthigesu has nothing to disclose. Ms. Macintyre has nothing to disclose. The institution of Alex MacKenzie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. Dr. Mah has nothing to disclose. Mr. McCullough has received personal compensation for serving as an employee of Hoffmann-La Roche Limited. Mr. McCullough has stock in Roche Holding AG. Ms. Ng has received personal compensation for serving as an employee of Research Institute of the McGill University Health Centre. Ms. Opalka has received personal compensation for serving as an employee of Transition Technologies PSC . Ms. Opalka has received personal compensation for serving as an employee of Technical University of Lodz. Ms. Opalka has received personal compensation in the range of $500-$4,999 for serving as a Academic teacher with Technical University of Lodz. Ms. Opalka has received personal compensation in the range of $10,000-$49,999 for serving as a PhD candidate with Technical University of Lodz. Mr. Openchowski has received personal compensation for serving as an employee of Roche. Mr. Openchowski has stock in Roche. Svetlana Petkun has received personal compensation for serving as an employee of Hoffmann-La Roche Inc.. The institution of Dr. Potter has received research support from Cambrooke Ajimoto. The institution of Dr. Potter has received research support from Nutricia. The institution of Dr. Potter has received research support from Biomarin. The institution of Dr. Sheriko has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Sheriko has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Sheriko has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen. The institution of Dr. Sheriko has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Sheriko has received research support from MARS VR Labs. The institution of Dr. Sheriko has received research support from CIHR. The institution of Dr. Sheriko has received research support from IWK Health. Ms. Smith has nothing to disclose. Dr. Strahm has received personal compensation for serving as an employee of F. Hoffmann-La Roche. Ms. Turgeon Desilets has nothing to disclose. Ms. Woof has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ATOM. Ms. Woof has received personal compensation in the range of $50,000-$99,999 for serving as a Leader of Physiotherapy with BC Centre for Ability. Dr. Chen has nothing to disclose.

Objective: To create an evidence-based patient education resource to better support cancer patients with bone metastases in carrying out safe movements during activities of daily living, to maintain their bone health and reduce the risk of fractures. Methods: A quality improvement project was conducted in three phases: Development of the Resource, Preliminary Feedback and Revision, and French Canadian Translation. Results: The educational resource Living Safely with Bone Metastases focuses on safe movement, activities of daily living, and exercise, organized within the sections Move with care, Stay safe in different environments and Follow an exercise program prescribed by a physiotherapist. Translation yielded a Canadian French version Vivre en toute sécurité avec des métastases osseuses. Conclusion: Living Safely with Bone Metastases is an accessible online and paper resource for patients and healthcare professionals, in order to promote ongoing disease management of individuals with bone metastases. Innovation: Cancer patients with bone metastases are at high risk of pathological fractures however resources on fracture prevention are lacking. Living Safely with Bone Metastases is an innovative health education resource that fills an important gap in oncology practice and has the potential to reduce the occurrence of fractures.

Measurements of body composition using dual-energy X-ray absorptiometry (DXA) and single abdominal images from computed tomography (CT) in advanced cancer patients (ACP) have important diagnostic and prognostic value. The question arises as to whether CT scans can serve as surrogates for DXA in terms of whole-body fat-free mass (FFM), whole-body fat mass (FM), and appendicular skeletal muscle (ASM) mass. Predictive equations to estimate body composition for ACP from CT images have been proposed (Mourtzakis et al. 2008; Appl. Physiol. Nutr. Metabol. 33(5): 997-1006); however, these equations have yet to be validated in an independent cohort of ACP. Thus, this study evaluated the accuracy of these equations in estimating FFM, FM, and ASM mass using CT images at the level of the third lumbar vertebrae and compared these values with DXA measurements. FFM, FM, and ASM mass were estimated from the prediction equations proposed by Mourtzakis and colleagues (2008) using single abdominal CT images from 43 ACP and were compared with whole-body DXA scans using Spearman correlations and Bland-Altman analyses. Despite a moderate to high correlation between the actual (DXA) and predicted (CT) values for FM (rho = 0.93; p ≤ 0.001), FFM (rho = 0.78; p ≤ 0.001), and ASM mass (rho = 0.70; p ≤ 0.001), Bland-Altman analyses revealed large range-of-agreement differences between the 2 methods (29.39 kg for FFM, 15.47 kg for FM, and 3.99 kg for ASM mass). Based on the magnitude of these differences, we concluded that prediction equations using single abdominal CT images have poor accuracy, cannot be considered as surrogates for DXA, and may have limited clinical utility.